Contact Supplier

Contact Supplier

To get in touch with Evercyte GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    Evercyte to showcase latest EV cell factories and recombinant antigen recognition at ISEV 2023 Seattle

    news-releasesEvercyte GmbH
    May 9th 2023

    Vienna, Austria: – Innovative biotech manufacturer Evercyte will once again feature as a high profile presence at the Annual Meeting of the International Society of Extracellular Vesicles (ISEV 2023), this time in the US Northwestern city of Seattle.

    ISEV annual meetings have repeatedly provided Evercyte with a scientific platform from which to share knowledges and its latest advances in EV technology, with its co-founders, Assoc. Prof. Dr. Johannes and Regina Grillari, widely recognized as leading authorities in exosome research. Both will again be present at the meeting.

    Clinical grade EV production

    Evercyte’s latest product lines include its ‘cell factories’ for standardized production of clinical grade EVs based on mesenchymal stromal cells (MSCs) derived from human sources such as adipose tissue, bone marrow, placental tissue, amniotic membrane, dental pulp, etc.

    Current production lines include ASC/TERT300 (adipose-derived MSCs), BM-MSC/TERT292 (bone marrow- derived MSCs), P-MSC/TERT308 (placental amnion-derived MSCs), CP-MSC/TERT308 (chorionic plate-derived MSCs), DPSC/TERT334 (dental pulp-derived MSC), and WJ-MSC/TERT273 (Wharton’s jelly-derived MSC).

    Service portfolio

    “These cell lines have been established under xeno-free conditions, with full documentation of any manipulation step. This gives them the great advantage that they can be readily transferred to a GMP facility for generation of a master cell bank that can be used for production of clinical grade vesicles,” commented Assoc. Prof. Dr. Regina Grillari, who is Evercyte’s Chief Operating Officer.

    Evercyte constant expanding services portfolio, now includes lab-scale production of EVs from customer-derived cells, enrichment and characterization of EVs, and testing EVs for anti-fibrotic, anti-inflammatory, neo-angiogenic, wound-healing and other biological activities.

    Antigen recognition

    Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs for specific tissues in targeted drug delivery.

    During OF 16 Drug Delivery (Track 4) at the conference, Dr. Madhusudhan Bobbili from Assoc. Prof.  Johannes Grillari’s lab at the Ludwig Boltzmann Institute for Traumatology in Vienna will present ‘CD81-based combinatorial library for selecting recombinant extracellular vesicles to target EGFR and HER2 for drug delivery in vivo’ (Room 606/607, Friday, May 19, 1505 hrs.). Dr. Bobbili’s presentation is based on Evercyte’s patented technology of antigen recognition via binding marker proteins of EVs that seeks to establish a new model for yeast display methodology for the development of diverse non-antibody protein scaffolds towards the ability of antigen recognition.

    About Evercyte GmbH

    Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

    The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for the production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

    By providing native extracellular vesicles from mesenchymal stromal cells Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.

    Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.

    Learn more at:

    About ISEV 2023

    The International Society for Extracellular Vesicles is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes.

    With nearly 1,000 members, ISEV continues to be the leader in advancing the study of extracellular vesicles globally. Founded in 2012 in Sweden, ISEV is now headquartered in the USA. Through its programs and services, it provides essential training and research opportunities for those involved in exosome and microvesicle research.

    The ISEV Annual Meeting attracts some 1,000 attendees, including top researchers in the field discussing the latest in extracellular vesicles, exosomes, and microvesicles.

    ISEV 2023 is a five-day event opening May 17 at the Seattle Convention Center in Washington State, USA.

    The event is organized by the International Society of Extracellular Vesicles with further information at:


    Click on Evercyte supports study into extended yeast display libraries for CD81 LEL mutants for EV surface customization for more on antigen recognition.
    Click on Evercyte EV Cell Factories to learn more.
    Click on Evercyte EV Testing Services for further information

    Evercyte to showcase latest EV cell factories and recombinant antigen recognition at ISEV 2023 Seattle

    Assoc.Prof. Dr. Regina Grillari, Chief Operating Officer, will lead Evercyte’s presence at ISEV 2023 in Seattle, USA.

    Contact Evercyte GmbH

    Simply fill out the form below to contact Evercyte GmbH now.

    Send Evercyte GmbH a Message